RESTORING GLYCEMIC CONTROL

Digma Medical

​Type 2 Diabetes and other metabolic diseases (such as NASH) are associated with diminishing capacity of the body to control glucose levels. Duodenal Glycemic Control™ is a safe, 30 minute, minimally-invasive therapeutic procedure that uses Digma Medical's product - DiaGone™ to restore the body's natural ability to control glucose, with NO implant.

 

WHO WE ARE

Digma Medical is a clinical stage medical technology company revolutionizing the treatment of Type 2 Diabetes and other metabolic syndrome disease such as NASH. Founded in 2013 and backed by leading venture capital firms, Digma is dedicated to the development of our patented technology, DiaGone™ to treat insulin resistance - the underlying mechanism of the disease. DiaGone™ is now in
a multi-center clinical study in Spain, Israel and the Czech Republic.

 

DIAGONE™

Safe. One-time. No implant.
Diabetes, Now Gone!

DiaGone™ is an endoscopic, disposable device, that uses state of the art laser technology to treat the duodenum.
The Duodenal Glycemic Control™ procedure is a 30 minute GI procedure, in which the gastroenterologist uses  DiaGone™ to treat the duodenum for restoring the natural ability of the body to control glucose levels.

 

DIGMA MEDICAL TEAM

 

JAMES MCNALLY, MBA, MSC

President, CEO

James joined Digma as President and CEO in 2020.  Prior to Digma, Mr. McNally was a member of the senior leadership team at GenMark Diagnostics (NASDAQ: GNMK) where he led the global commercial organization.  Prior to GenMark, he held roles of increasing responsibility with Volcano Corporation (acquired by Philips) in sales, marketing and general management.  James has also worked in research and development with Boston Scientific’s Endosurgery business unit and he began his career in Morgan Stanley’s investment banking division.  Mr. McNally received a B.S.E. in Electrical Engineering with high honors from Princeton University, an M.S. degree in Optical Sciences from the University of Arizona, and an M.B.A. with high distinction from Harvard Business School where he was a George F. Baker Scholar and a Robert S. Kaplan Life Sciences Fellow.

DR. IRIT YANIV, MD, MBA

Co-Founder, Chairperson

Irit Yaniv is an experienced and accomplished senior executive in the medtech industry, and has held CEO positions with medical device companies Impulse Dynamics and MetaCure. In parallel to her position at Digma, Irit is a Venture Partner at Accelmed VC, where she leads the early stage portfolio investments. Dr. Yaniv holds an MD degree from the Ben-Gurion University and an MBA from the Recanati Business School of Tel Aviv University.

DR. BRIAN L. LEVY, MD, FACE

Medical Director

Dr Levy brings over 25 years of clinical and research experiences within the endocrinology, diabetes and metabolism community. Prior to Digma, Dr. Levy was Chief Medical Officer & Worldwide VP of Clinical Affairs of Johnson & Johnson Diabetes Care Companies (Animas, Calibra, LifeScan, JJDI) where he oversaw all of clinical and medical affairs of the group. Before J&J Diabetes Care, Dr. Levy served as Global Medical Affairs Leader for Metabolic Disease at Janssen Pharma at J&J, where he led the INVOKANA (canagliflozin) medical affairs program. Dr. Levy was on faculty at NYU school of medicine, where he remains an attending physician at Bellevue Hospital NYC. Dr. Levy received his BA at Cornell U, his MD from Johns Hopkins University School of Medicine, and completed his residency & fellowship in Endocrinology & Metabolism at NYU Medical Center.

ILAN BEN-OREN

Co-Founder, CTO

Ilan brings more than 20 years experience in R&D and management in the medical device arena. Prior to joining Digma Medical, he served as the CTO of Exalenz Bioscience Ltd., (TASE:EXEN) and Oridion Medical (SWX:ORIDN). Mr. Ben Oren is the author of more than 40 patents and patent applications in the field of medical technologies and electro-optics. Mr. Ben-Oren holds a master’s degree in applied physics and the science of materials summa-cum-laude from the Hebrew University of Jerusalem.

YANIV KIRMA, BSC

COO, Site Manager

Yaniv has over 20 years of experience in leading large and small scale cross-organizational teams in the medical and defense industry, including management of multidisciplinary R&D and operation projects and teams. Prior to joining Digma, Yaniv was VP R&D and Site Manager of Endochoice Innovation Center that was acquired by Boston Scientific in 2016.
Mr. Kirma holds a BSc in electrical Engineering and Physics from the Technion, Haifa.

HILA DAGAN, PHD

Regulatory Manager

Hila has over 10 years of experience in medical device regulatory, clinical affairs and quality assurance. Prior to Digma, Hila was VP Clinical and Regulatory affairs in a wearable telemedicine startup where she built and lead the regulatory strategy, clinical affairs and quality system infrastructure. Earlier, Hila was a researcher and project manager in other medical device companies in the field of wound care and stem cells regenerative medicine. Dr. Dagan holds a PhD in Biotechnology from Tel Aviv University in the field of nano-biotechnology.

AVIA HERSCHKOVITZ, PHD

Director of Research & QA Manager

Avia has over 12 years experience in research, animal trials and modeling, in-vivo, ex-vivo & in-vitro experimentation. Prior to Digma Avia was an analyst in a venture capital fund where he was in charge of research & IP. Dr. Herschkovitz holds a PhD in molecular cell biology from the Weizmann Institute of Science in the field of diabetes, obesity and insulin resistance research.

DIGMA MEDICAL INVESTORS

Digma Medical is a privately held company, backed by these leading venture capital firms

Accelmed
Arkin Holdings
Peregrine
 
 

©2017 BY DIGMA MEDICAL. PROUDLY CREATED WITH WIX.COM